VKTX241004C72000
- 0.05
- -0.10-66.67%
Viking Therapeutics Newsroom
Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $105
Viking Therapeutics Analyst Ratings
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $138
Stifel Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $95
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
Truist Financial Sticks to Their Buy Rating for Viking Therapeutics (VKTX)
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $105
Morgan Stanley Reiterates Overweight on Viking Therapeutics, Maintains $105 Price Target
Buy Rating Affirmed for Viking Therapeutics as VK2735 Shows Promising Weight Loss and Safety Profile
viking therapeutics (VKTX.US) rose over 11% on Wednesday! Received a 'shareholding' rating from Morgan Stanley.
Viking Therapeutics Analyst Ratings
JPMorgan Initiates Viking Therapeutics at Overweight With $80 Price Target
J.P. Morgan Initiates Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $80
Buy Rating on Viking Therapeutics Backed by Promising Obesity Drug VK-2735 and Market Potential
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $120
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $120
Buy Rating on Viking Therapeutics: A Strategic Opportunity Amid Market Overreaction
Deutsche Bank praises Eli Lilly and Co (LLY.US) as a "high-growth unicorn", with a target price skyrocketing to $1025.
Buy Rating on Viking Therapeutics: Promising VK2735 Development and Strategic Advancements